Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity.
Visceral adipose tissue (VAT) is an important risk factor for obesity-related metabolic disorders. Therefore, a reduction in VAT has become a key goal in obesity management. However, VAT is correlated with intrahepatic triglyceride (IHTG) content, so it is possible that IHTG, not VAT, is a better marker of metabolic disease. We determined the independent association of IHTG and VAT to metabolic function, by evaluating groups of obese subjects, who differed in IHTG content (high or normal) but matched on VAT volume or differed in VAT volume (high or low) but matched on IHTG content. Stable isotope tracer techniques and the euglycemic-hyperinsulinemic clamp procedure were used to assess insulin sensitivity and very-low-density lipoprotein-triglyceride (VLDL-TG) secretion rate. Tissue biopsies were obtained to evaluate cellular factors involved in ectopic triglyceride accumulation. Hepatic, adipose tissue and muscle insulin sensitivity were 41, 13, and 36% lower (P < 0.01), whereas VLDL-triglyceride secretion rate was almost double (P < 0.001), in subjects with higher than normal IHTG content, matched on VAT. No differences in insulin sensitivity or VLDL-TG secretion were observed between subjects with different VAT volumes, matched on IHTG content. Adipose tissue CD36 expression was lower (P < 0.05), whereas skeletal muscle CD36 expression was higher (P < 0.05), in subjects with higher than normal IHTG. These data demonstrate that IHTG, not VAT, is a better marker of the metabolic derangements associated with obesity. Furthermore, alterations in tissue fatty acid transport could be involved in the pathogenesis of ectopic triglyceride accumulation by redirecting plasma fatty acid uptake from adipose tissue toward other tissues.
Fabbrini
Elisa
E
Center for Human Nutrition and Atkins Center of Excellence in Obesity Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Magkos
Faidon
F
Mohammed
B Selma
BS
Pietka
Terri
T
Abumrad
Nada A
NA
Patterson
Bruce W
BW
Okunade
Adewole
A
Klein
Samuel
S
D001823:Body Composition; D018955:CD36 Antigens / Q000378:metabolism; D017931:DNA Primers; D005260:Female; D005947:Glucose / Q000378:metabolism; D015309:Glucose Clamp Technique; D006801:Humans; D050152:Intra-Abdominal Fat / Q000378:metabolism / Q000473:pathology; D008079:Lipoproteins, VLDL / Q000032:analysis; D008099:Liver / Q000737:chemistry*; D008297:Male; D008659:Metabolic Diseases / Q000209:etiology*; D009765:Obesity / Q000150:complications*; D010168:Palmitates / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014280:Triglycerides / Q000032:analysis*
D018955:CD36 Antigens; D017931:DNA Primers; D008079:Lipoproteins, VLDL; D010168:Palmitates; D014280:Triglycerides; D005947:Glucose
J Lipid Res. 2009 Apr;50 Suppl:S86-90
19033209
N Engl J Med. 2004 Jun 17;350(25):2549-57
15201411
J Biol Chem. 2001 Nov 2;276(44):40567-73
11504711
Gastroenterology. 2007 Jan;132(1):282-93
17241878
J Clin Invest. 2000 Jul;106(2):171-6
10903330
J Clin Endocrinol Metab. 2002 Nov;87(11):5098-103
12414878
J Lipid Res. 2002 Feb;43(2):223-33
11861664
Nat Med. 2001 Aug;7(8):947-53
11479628
Diabetes Care. 2002 Mar;25(3):431-8
11874926
J Clin Invest. 2003 Jul;112(1):91-100
12840063
Nat Med. 2001 Aug;7(8):941-6
11479627
J Clin Invest. 2005 May;115(5):1343-51
15864352
J Cardiometab Syndr. 2007 Spring;2(2):136-8
17684473
Obes Res. 1998 Apr;6 Suppl 1:8S-17S
9569171
Am J Physiol Endocrinol Metab. 2005 Feb;288(2):E462-8
15339742
J Clin Endocrinol Metab. 2003 Nov;88(11):5444-51
14602787
J Clin Invest. 1995 Jan;95(1):158-66
7814610
Biochim Biophys Acta. 2005 Oct 1;1736(3):163-80
16198626
J Lipid Res. 2007 May;48(5):1204-11
17325388
J Clin Endocrinol Metab. 2007 Feb;92(2):720-4
17148569
Obesity (Silver Spring). 2006 Feb;14 Suppl 1:16S-19S
16642958
Gastroenterology. 2008 Feb;134(2):424-31
18242210
N Engl J Med. 2006 Nov 30;355(22):2297-307
17135584
Nature. 2006 Dec 14;444(7121):881-7
17167477
Am J Physiol Gastrointest Liver Physiol. 2008 May;294(5):G1281-7
18388185
Diabetes. 2001 Aug;50(8):1844-50
11473047
J Biol Chem. 2008 May 16;283(20):13578-85
18353783
Am J Physiol Endocrinol Metab. 2003 Mar;284(3):E549-56
12475754
J Clin Invest. 2004 Jul;114(2):147-52
15254578
Am J Physiol. 1956 Sep;187(1):15-24
13362583
J Clin Invest. 2007 Sep;117(9):2621-37
17717599
Diabetes. 2007 Jul;56(7):1872-80
17440173
FASEB J. 2004 Jul;18(10):1144-6
15132977
J Clin Invest. 2004 Jun;113(11):1530-2
15173878
Endocrinol Metab Clin North Am. 2008 Sep;37(3):635-46, viii-ix
18775356
Biochemistry. 2004 Apr 13;43(14):4179-87
15065861
Am J Physiol Endocrinol Metab. 2006 Feb;290(2):E355-62
16219668
Diabetes Care. 1999 Sep;22(9):1462-70
10480510
J Lipid Res. 1999 Nov;40(11):2118-24
10553015
Int J Obes Relat Metab Disord. 2004 Dec;28 Suppl 4:S12-21
15592481
Epidemiol Rev. 2007;29:77-87
17478441
J Clin Invest. 2004 Jun;113(11):1582-8
15173884
Diabetologia. 2006 Apr;49(4):755-65
16463046
Diabetes. 2002 Oct;51(10):3113-9
12351456
Diabetes. 2007 Apr;56(4):1010-3
17287468
Diabetes Metab. 2003 Nov;29(5):478-85
14631324
BMC Cell Biol. 2008 Aug 13;9:45
18700980
Acta Physiol (Oxf). 2007 Jul;190(3):209-19
17394567
Am J Physiol Endocrinol Metab. 2007 Dec;293(6):E1663-9
17911339
J Clin Endocrinol Metab. 2006 Nov;91(11):4459-66
16926254
Gastroenterology. 2008 May;134(5):1369-75
18355813